Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

This study is currently recruiting participants.

Verified by AstraZeneca, April 2008

First Received: December 13, 2007 Last Updated: April 14, 2008 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00573742

Purpose

The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.

Condition	Intervention
Primary Hypertension	Drug: Candesartan Cilexeotil 16mg

Study Type:	Observational
Study Design:	Prospective
Official Title:	Non-Interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or Add-on Therapy.

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: CV 11974 Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	2150
Study Start Date:	September 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

diagnosis of essential hypertension (mild or moderate as defined in European Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved Atacand SPC. Written informed consent to allow access and use(analysis) of data collected

Exclusion Criteria:

Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573742

Contacts

Contact: AstraZeneca Romania Medical Department Clinical Study, Information

+4021 317 60 41

otilia.radu@astrazeneca.com

Locations

Romania
Research Site	Recruiting
Bucuresti, Romania
Research Site	Recruiting
Bacau, Romania
Research Site	Recruiting
Braila, Romania
Research Site	Recruiting
Brasov, Romania
Research Site	Recruiting
Cluj, Romania
Research Site	Recruiting
Constanta, Romania
Research Site	Recruiting
Craiova, Romania
Research Site	Recruiting
Galati, Romania
Research Site	Recruiting
Timisoara, Romania
Research Site	Recruiting
Iasi, Romania
Research Site	Recruiting
Lugoj, Romania
Research Site	Recruiting
Oradea, Romania
Research Site	Recruiting
Pitesti, Romania
Research Site	Recruiting
Ploiesti, Romania
Research Site	Recruiting
Sibiu, Romania
Research Site	Recruiting
Ghiroda, Romania

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Cristina Pentiuc

AstraZeneca

More Information

No publications provided

Study ID Numbers:	NIS-ATO-HCH-2007/2
Study First Received:	December 13, 2007
Last Updated:	April 14, 2008
ClinicalTrials.gov Identifier:	NCT00573742 History of Changes
Health Authority:	Romainia: National Drug Agency

Keywords provided by AstraZeneca:

hypertension

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Candesartan cilexetil
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Candesartan
Vascular Diseases

Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010